The metalloprotease-disintegrin ADAM8 contributes to temozolomide chemoresistance and enhanced invasiveness of human glioblastoma cells
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The metalloprotease-disintegrin ADAM8 contributes to temozolomide chemoresistance and enhanced invasiveness of human glioblastoma cells
Authors
Keywords
-
Journal
NEURO-ONCOLOGY
Volume 17, Issue 11, Pages 1474-1485
Publisher
Oxford University Press (OUP)
Online
2015-04-01
DOI
10.1093/neuonc/nov042
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Protective effects of ADAM8 against cisplatin-mediated apoptosis in non-small-cell lung cancer
- (2013) Weifeng Zhang et al. CELL BIOLOGY INTERNATIONAL
- Tunicamycin Potentiates Cisplatin Anticancer Efficacy through the DPAGT1/Akt/ABCG2 Pathway in Mouse Xenograft Models of Human Hepatocellular Carcinoma
- (2013) H. Hou et al. MOLECULAR CANCER THERAPEUTICS
- Abstract 3828: Potent curcumin analogues inhibit pancreatic cancer cell growth and angiogenesis
- (2012) Ganji Purnachandra Nagaraju et al. CANCER RESEARCH
- Temozolomide Dosing Regimens for Glioma Patients
- (2012) Herwig M. Strik et al. Current Neurology and Neuroscience Reports
- Targeting the Akt-pathway to Improve Radiosensitivity in Glioblastoma
- (2012) Ravi S. Narayan et al. CURRENT PHARMACEUTICAL DESIGN
- The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells
- (2012) Tor-Christian Aase Johannessen et al. NEURO-ONCOLOGY
- EGFR-Targeted Therapy in Malignant Glioma: Novel Aspects and Mechanisms of Drug Resistance
- (2012) Hui-Wen Lo Current Molecular Pharmacology
- L1CAM regulates DNA damage checkpoint response of glioblastoma stem cells through NBS1
- (2011) Lin Cheng et al. EMBO JOURNAL
- Overexpression of a disintegrin and metalloprotease 8 in human gliomas is implicated in tumor progression and prognosis
- (2011) Shiming He et al. MEDICAL ONCOLOGY
- Chemoresistance of glioblastoma cancer stem cells - much more complex than expected
- (2011) Dagmar Beier et al. Molecular Cancer
- ADAM17 promotes glioma cell malignant phenotype
- (2011) Xuguang Zheng et al. MOLECULAR CARCINOGENESIS
- MMP-2 siRNA Inhibits Radiation-Enhanced Invasiveness in Glioma Cells
- (2011) Aruna Venkata Badiga et al. PLoS One
- Matrix Metalloproteinases Contribute Distinct Roles in Neuroendocrine Prostate Carcinogenesis, Metastasis, and Angiogenesis Progression
- (2010) L. E. Littlepage et al. CANCER RESEARCH
- PI3K/Akt Signalling Pathway Specific Inhibitors: A Novel Strategy to Sensitize Cancer Cells to Anti-Cancer Drugs
- (2010) Marco Falasca CURRENT PHARMACEUTICAL DESIGN
- Inhibition of metalloproteinases derived from tumours: new insights in the treatment of human glioblastoma
- (2010) P. Gabelloni et al. NEUROSCIENCE
- Nuclear translocation and signalling of L1-CAM in human carcinoma cells requires ADAM10 and presenilin/γ-secretase activity
- (2009) Svenja Riedle et al. BIOCHEMICAL JOURNAL
- Temozolomide in malignant gliomas: current use and future targets
- (2009) J. Lee Villano et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The ADAM metalloproteinases
- (2008) D EDWARDS et al. MOLECULAR ASPECTS OF MEDICINE
- Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts
- (2008) Gaspar J. Kitange et al. NEURO-ONCOLOGY
- Adenovirus-mediated transfer of siRNA against MMP-2 mRNA results in impaired invasion and tumor-induced angiogenesis, induces apoptosis in vitro and inhibits tumor growth in vivo in glioblastoma
- (2008) O Kargiotis et al. ONCOGENE
- Expression of matrix metalloproteinases MMP-1, MMP-11 and MMP-19 is correlated with the WHO-grading of human malignant gliomas
- (2007) Jelena Stojic et al. NEUROSCIENCE RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started